Login Register Cart 0
Generic placeholder image

Reviews on Recent Clinical Trials

Editor-in-Chief

ISSN (Print): 1574-8871
ISSN (Online): 1876-1038

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Cross-Sectional Study

Satisfaction with Social Roles and Physical Function in Immune-mediated Inflammatory Diseases: A Cross-Sectional Study

Author(s): Rocco Spagnuolo*, Francesco Salvatore Iaquinta, Daniele Mauro, Ilenia Pantano, Stefano Dastoli, Saverio Naty, Cristina Cosco, Rosellina Margherita Mancina, Daniela Iacono, Emanuela Gaggiano, Annarita Ruggiero, Steven Paul Nisticò, Francesco Ciccia, Rosa Daniela Grembiale and Doldo Patrizia

Volume 17, Issue 3, 2022

Published on: 22 August, 2022

Page: [177 - 186] Pages: 10

DOI: 10.2174/1574887117666220531162104

Price: $65

conference banner
Abstract

Background: Although mood disorders have been well characterized by immunemediated inflammatory diseases, physical function and satisfaction with social roles have not yet been defined as independent domains.

Objective: The study aims to assess satisfaction with social roles and physical function alterations in a population with immune-mediated inflammatory diseases and identify associated characteristics.

Methods: Physical function and social role satisfaction were evaluated through the Patientreported Outcomes Measurement System. Besides comparison between groups, univariate and multivariable logistic regression analyses were performed to identify independent predictors.

Results: Two hundred sixty-five patients with immune-mediated inflammatory diseases and 206 controls were recruited. Compared to controls, patients with inflammatory bowel diseases had impaired physical function (p<0.001), while patients with inflammatory arthritis reported impairment in both domains (p<0.001, each). In the univariate logistic regression, gender, high school educational level, physical activity, and occupation were positively associated with physical function and social role satisfaction (p<0.001; p=0.001; p<0.001; p=0.001 and p<0.001; p=0.012; p=0.008; p=0.004, respectively). Active disease and steroids were inversely associated with physical function and social roles satisfaction (p=0.033; p=0.022 and p=0.002; p=0.038, respectively). Further associations were found between age and physical function (p=0.002) and biological treatment and ESR with social roles satisfaction (p<0.001; p=0.043; respectively). In the multivariable regression, gender was found to be associated with physical function (p<0.001) and social roles satisfaction (p=0.003). Negatively associated factors were biological treatment for satisfaction with social roles (p<0.001) and steroids for physical function (p=0.021), and social roles satisfaction (p=0.018).

Conclusion: Immune-mediated inflammatory diseases determine alterations in physical function and social life satisfaction. Gender and treatment are independently associated factors. Patientreported outcomes should be considered in clinical management to define patients’ real needs.

Keywords: Immune-mediated inflammatory diseases, PROMIS, inflammatory bowel disease, inflammatory arthritis, psoriasis, physical function, social satisfaction.

« Previous Next »
[1]
Rahman P, Inman RD, El-Gabalawy H, Krause DO. Pathophysiology and pathogenesis of immune-mediated inflammatory diseases: Commonalities and differences. J Rheumatol Suppl 2010; 85(0): 11-26.
[http://dx.doi.org/10.3899/jrheum.091462] [PMID: 20436162]
[2]
Scharloo M, Kaptein AA, Weinman J, et al. Illness perceptions, coping and functioning in patients with rheumatoid arthritis, chronic obstructive pulmonary disease and psoriasis. J Psychosom Res 1998; 44(5): 573-85.
[http://dx.doi.org/10.1016/S0022-3999(97)00254-7] [PMID: 9623878]
[3]
Marrie RA, Walld R, Bolton JM, et al. CIHR team in defining the burden and managing the effects of psychiatric comorbidity in chronic immunoinflammatory disease. Increased incidence of psychiatric disorders in immune-mediated inflammatory disease. J Psychosom Res 2017; 101: 17-23.
[http://dx.doi.org/10.1016/j.jpsychores.2017.07.015] [PMID: 28867419]
[4]
Katchamart W, Narongroeknawin P, Chanapai W, Thaweeratthakul P, Srisomnuek A. Prevalence of and factors associated with depression and anxiety in patients with rheumatoid arthritis: A multicenter prospective cross-sectional study. Int J Rheum Dis 2020; 23(3): 302-8.
[http://dx.doi.org/10.1111/1756-185X.13781] [PMID: 31908153]
[5]
Neuendorf R, Harding A, Stello N, Hanes D, Wahbeh H. Depression and anxiety in patients with Inflammatory Bowel Disease: A systematic review. J Psychosom Res 2016; 87: 70-80.
[http://dx.doi.org/10.1016/j.jpsychores.2016.06.001] [PMID: 27411754]
[6]
Pollo CF, Miot HA, Matos TDS, et al. Prevalence and factors associated with depression and anxiety in patients with psoriasis. J Clin Nurs 2021; 30(3-4): 572-80.
[http://dx.doi.org/10.1111/jocn.15577] [PMID: 33258200]
[7]
Parkinson JT, Foley ÉM, Jadon DR, Khandaker GM. Depression in patients with spondyloarthritis: prevalence, incidence, risk factors, mechanisms and management. Ther Adv Musculoskelet Dis 2020.
[http://dx.doi.org/10.1177/1759720X20970028]
[8]
IsHak WW, Pan D, Steiner AJ, et al. Patient-reported outcomes of quality of life, functioning, and GI/Psychiatric symptom severity in patients with inflammatory bowel disease (IBD). Inflamm Bowel Dis 2017; 23(5): 798-803.
[http://dx.doi.org/10.1097/MIB.0000000000001060] [PMID: 28301432]
[9]
Salaffi F, Di Carlo M, Carotti M, Farah S, Ciapetti A, Gutierrez M. The impact of different rheumatic diseases on health-related quality of life: A comparison with a selected sample of healthy individuals using SF-36 questionnaire, EQ-5D and SF-6D utility values. Acta Biomed 2019; 89(4): 541-57.
[PMID: 30657123]
[10]
de Korte J, Sprangers MA, Mombers FM, Bos JD. Quality of life in patients with psoriasis: A systematic literature review. J Investig Dermatol Symp Proc 2004; 9(2): 140-7.
[http://dx.doi.org/10.1046/j.1087-0024.2003.09110.x] [PMID: 15083781]
[11]
Gudu T, Gossec L. Quality of life in psoriatic arthritis. Expert Rev Clin Immunol 2018; 14(5): 405-17.
[http://dx.doi.org/10.1080/1744666X.2018.1468252] [PMID: 29681202]
[12]
Borman P, Toy GG, Babaoğlu S, Bodur H, Ciliz D, Alli N. A comparative evaluation of quality of life and life satisfaction in patients with psoriatic and rheumatoid arthritis. Clin Rheumatol 2007; 26(3): 330-4.
[http://dx.doi.org/10.1007/s10067-006-0298-y] [PMID: 16622591]
[13]
Janke K-H, Raible A, Bauer M, et al. Questions on life satisfaction (FLZM) in inflammatory bowel disease. Int J Colorectal Dis 2004; 19(4): 343-53.
[http://dx.doi.org/10.1007/s00384-003-0522-z] [PMID: 14586630]
[14]
Eskin M, Savk E, Uslu M, Küçükaydoğan N. Social problem-solving, perceived stress, negative life events, depression and life satisfaction in psoriasis. J Eur Acad Dermatol Venereol 2014; 28(11): 1553-9.
[http://dx.doi.org/10.1111/jdv.12355] [PMID: 24404894]
[15]
Weldring T, Smith SMS. Patient-Reported Outcomes (PROs) and Patient-Reported Outcome Measures (PROMs). Health Serv Insights 2013; 6: 61-8.
[http://dx.doi.org/10.4137/HSI.S11093] [PMID: 25114561]
[16]
Boyce MB, Browne JP, Greenhalgh J. The experiences of professionals with using information from patient-reported outcome measures to improve the quality of healthcare: a systematic review of qualitative research. BMJ Qual Saf 2014; 23(6): 508-18.
[http://dx.doi.org/10.1136/bmjqs-2013-002524] [PMID: 24505110]
[17]
Jette DU, Halbert J, Iverson C, Miceli E, Shah P. Use of standardized outcome measures in physical therapist practice: perceptions and applications. Phys Ther 2009; 89(2): 125-35.
[http://dx.doi.org/10.2522/ptj.20080234] [PMID: 19074618]
[18]
Cella D, Yount S, Rothrock N, et al. The patient-reported outcomes measurement information system (PROMIS): Progress of an NIH roadmap cooperative group during its first two years. Med Care 2007; 45(5) (Suppl. 1): S3-S11.
[http://dx.doi.org/10.1097/01.mlr.0000258615.42478.55] [PMID: 17443116]
[19]
Aletaha D, Neogi T, Silman AJ, et al. 2010 Rheumatoid arthritis classification criteria: An American college of Rheumatology/European league against rheumatism collaborative initiative. Arthritis Rheum 2010; 62(9): 2569-81.
[http://dx.doi.org/10.1002/art.27584] [PMID: 20872595]
[20]
Taylor W, Gladman D, Helliwell P, Marchesoni A, Mease P, Mielants H. Classification criteria for psoriatic arthritis: Development of new criteria from a large international study. Arthritis Rheum 2006; 54(8): 2665-73.
[http://dx.doi.org/10.1002/art.21972] [PMID: 16871531]
[21]
Rudwaleit M, van der Heijde D, Landewé R, et al. The development of Assessment of SpondyloArthritis international Society classification criteria for axial spondyloarthritis (part II): Validation and final selection. Ann Rheum Dis 2009; 68(6): 777-83.
[http://dx.doi.org/10.1136/ard.2009.108233] [PMID: 19297344]
[22]
Prevoo ML, van ’t Hof MA, Kuper HH, van Leeuwen MA, van de Putte LB, van Riel PL. Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 1995; 38(1): 44-8.
[http://dx.doi.org/10.1002/art.1780380107] [PMID: 7818570]
[23]
Michelsen B, Sexton J, Smolen JS, et al. Can disease activity in patients with psoriatic arthritis be adequately assessed by a modified Disease Activity index for PSoriatic Arthritis (DAPSA) based on 28 joints? Ann Rheum Dis 2018; 77(12): 1736-41.
[http://dx.doi.org/10.1136/annrheumdis-2018-213463] [PMID: 30237203]
[24]
Machado P, Landewé R, Lie E, et al. Assessment of SpondyloArthritis international Society. Ankylosing Spondylitis Disease Activity Score (ASDAS): Defining cut-off values for disease activity states and improvement scores. Ann Rheum Dis 2011; 70(1): 47-53.
[http://dx.doi.org/10.1136/ard.2010.138594] [PMID: 21068095]
[25]
Harvey RF, Bradshaw JM. A simple index of Crohn’s-disease activity. Lancet 1980; 1(8167): 514.
[http://dx.doi.org/10.1016/S0140-6736(80)92767-1] [PMID: 6102236]
[26]
Rutgeerts P, Sandborn WJ, Feagan BG, et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med 2005; 353(23): 2462-76.
[http://dx.doi.org/10.1056/NEJMoa050516] [PMID: 16339095]
[27]
Fredriksson T, Pettersson U. Severe psoriasis--oral therapy with a new retinoid. Dermatologica 1978; 157(4): 238-44.
[http://dx.doi.org/10.1159/000250839] [PMID: 357213]
[28]
Calvert M, Kyte D, Mercieca-Bebber R, et al. Guidelines for inclusion of patient-reported outcomes in clinical trial protocols: The SPIRIT-PRO extension. JAMA 2018; 319(5): 483-94.
[http://dx.doi.org/10.1001/jama.2017.21903] [PMID: 29411037]
[29]
Mancina RM, Pagnotta R, Pagliuso C, et al. Gastrointestinal symptoms of and psychosocial changes in Inflammatory bowel disease: A nursing-led cross-sectional study of patients in clinical remission. Medicina (Kaunas) 2020; 56(1): 56.
[http://dx.doi.org/10.3390/medicina56010045] [PMID: 31968710]
[30]
Hahn EA, Beaumont JL, Pilkonis PA, et al. The PROMIS satisfaction with social participation measures demonstrated responsiveness in diverse clinical populations. J Clin Epidemiol 2016; 73: 135-41.
[http://dx.doi.org/10.1016/j.jclinepi.2015.08.034] [PMID: 26931288]
[31]
Fries JF, Bruce B, Bjorner J, Rose M. More relevant, precise, and efficient items for assessment of physical function and disability: moving beyond the classic instruments. Ann Rheum Dis 2006; 65 (Suppl. 3): iii16-21.
[http://dx.doi.org/10.1136/ard.2006.059279] [PMID: 17038464]
[32]
Eder L, Thavaneswaran A, Chandran V, Gladman DD. Gender difference in disease expression, radiographic damage and disability among patients with psoriatic arthritis. Ann Rheum Dis 2013; 72(4): 578-82.
[http://dx.doi.org/10.1136/annrheumdis-2012-201357] [PMID: 22589379]
[33]
Kozlov N, Benzon HT. Role of gender and race in patient-reported outcomes and satisfaction. Anesthesiol Clin 2020; 38(2): 417-31.
[http://dx.doi.org/10.1016/j.anclin.2020.01.012] [PMID: 32336393]
[34]
Leone D, Gilardi D, Corrò BE, et al. Psychological characteristics of inflammatory bowel disease patients: A comparison between active and nonactive patients. Inflamm Bowel Dis 2019; 25(8): 1399-407.
[http://dx.doi.org/10.1093/ibd/izy400] [PMID: 30689871]
[35]
Fernández-Carballido C, Martín-Martínez MA, García-Gómez C, et al. Impact of comorbidity on physical function in patients with ankylosing spondylitis and psoriatic arthritis attending rheumatology clinics: Results from a cross-sectional study. Arthritis Care Res (Hoboken) 2020; 72(6): 822-8.
[http://dx.doi.org/10.1002/acr.23910] [PMID: 31033231]
[36]
Kavanaugh A, Antoni C, Krueger GG, et al. Infliximab improves health related quality of life and physical function in patients with psoriatic arthritis. Ann Rheum Dis 2006; 65(4): 471-7.
[http://dx.doi.org/10.1136/ard.2005.040196] [PMID: 16096330]
[37]
van der Heijde D, Breban M, Halter D, et al. Maintenance of improvement in spinal mobility, physical function and quality of life in patients with ankylosing spondylitis after 5 years in a clinical trial of adalimumab. Rheumatology (Oxford) 2015; 54(7): 1210-9.
[http://dx.doi.org/10.1093/rheumatology/keu438] [PMID: 25541333]

Rights & Permissions Print Cite
Article Metrics
1
© 2024 Bentham Science Publishers | Privacy Policy